---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058866"
form_type: "8-K/A"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:18:21.474935+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunogenX reports net loss of $8.86M in 2023; auditor cites going concern doubts

## Summary
- Net loss for 2023 was $8.86M, compared to $3.62M in 2022 and $1.66M in 2021.
- Total assets of $4.1M vs. total liabilities of $18.33M as of Dec 31, 2023, resulting in stockholders' deficit of $14.23M.
- Cash and cash equivalents only $251k as of Dec 31, 2023; auditor expressed substantial doubt about going concern.
- Pre-revenue clinical-stage biotherapeutics company focused on celiac disease treatments.

## SEC filing metadata
- accession: 0001104659-24-058866
- form_type: 8-K/A
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465924058866/0001104659-24-058866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465924058866/tm2413822d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058866
- JSON: https://secwatch.observer/filing/0001104659-24-058866.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.